• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

哮喘的异质性与严重程度。

Asthma heterogeneity and severity.

作者信息

Carr Tara F, Bleecker Eugene

机构信息

Asthma and Airway Disease Research Center, University of Arizona, 1501 N Campbell Ave, Tucson, AZ 85724-5030 USA.

Center for Genomics and Personalized Medicine Research, Wake Forest School of Medicine, Winston-Salem, NC USA.

出版信息

World Allergy Organ J. 2016 Nov 29;9(1):41. doi: 10.1186/s40413-016-0131-2. eCollection 2016.

DOI:10.1186/s40413-016-0131-2
PMID:27980705
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5129643/
Abstract

Asthma is a common, chronic inflammatory airways disease characterized by a clinical syndrome of bronchial hyperresponsiveness, inflammation, and reversible airflow obstruction. Individuals with asthma can vary widely in clinical presentation, severity, and pathobiology. The incident factors, pathogenesis, prognosis, and treatment of asthma remain incompletely understood. Utilizing measurable characteristics of asthmatic patients, including demographic, physiologic, and biologic markers, can however identify meaningful phenotypic categories in asthma. Identification of these phenotypes may help improve precision therapeutics targeted toward an individual's' disease, and may identify strategies for preventing progression of disease severity.

摘要

哮喘是一种常见的慢性炎症性气道疾病,其特征为支气管高反应性、炎症和可逆性气流受限的临床综合征。哮喘患者的临床表现、严重程度和病理生物学存在很大差异。哮喘的发病因素、发病机制、预后和治疗仍未完全明确。然而,利用哮喘患者的可测量特征,包括人口统计学、生理学和生物学标志物,可以识别哮喘中有意义的表型类别。识别这些表型可能有助于提高针对个体疾病的精准治疗,并可能确定预防疾病严重程度进展的策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9697/5129643/5f93e01623b2/40413_2016_131_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9697/5129643/bc98bd2e26ee/40413_2016_131_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9697/5129643/2d57a9dc170f/40413_2016_131_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9697/5129643/5f93e01623b2/40413_2016_131_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9697/5129643/bc98bd2e26ee/40413_2016_131_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9697/5129643/2d57a9dc170f/40413_2016_131_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9697/5129643/5f93e01623b2/40413_2016_131_Fig3_HTML.jpg

相似文献

1
Asthma heterogeneity and severity.哮喘的异质性与严重程度。
World Allergy Organ J. 2016 Nov 29;9(1):41. doi: 10.1186/s40413-016-0131-2. eCollection 2016.
2
Understanding asthma pathophysiology.了解哮喘的病理生理学。
Allergy Asthma Proc. 2003 Mar-Apr;24(2):79-83.
3
Persistent airflow obstruction in patients with asthma: Characteristics of a distinct clinical phenotype.哮喘患者的持续性气流受限:一种独特临床表型的特征
Respir Med. 2015 Nov;109(11):1404-9. doi: 10.1016/j.rmed.2015.09.009. Epub 2015 Sep 21.
4
Asthma characteristics and biomarkers from the Airways Disease Endotyping for Personalized Therapeutics (ADEPT) longitudinal profiling study.气道疾病个性化治疗内型分析(ADEPT)纵向分析研究中的哮喘特征与生物标志物
Respir Res. 2015 Nov 17;16:142. doi: 10.1186/s12931-015-0299-y.
5
Small Airways: The "Silent Zone" of 2021 GINA Report?小气道:《2021年全球哮喘防治创议(GINA)报告》中的“沉默地带”?
Front Med (Lausanne). 2022 May 23;9:884679. doi: 10.3389/fmed.2022.884679. eCollection 2022.
6
Monoclonal antibodies targeting small airways: a new perspective for biological therapies in severe asthma.靶向小气道的单克隆抗体:重症哮喘生物治疗的新视角
Asthma Res Pract. 2022 Oct 17;8(1):6. doi: 10.1186/s40733-022-00088-2.
7
Potential role for phenotypic modulation of bronchial smooth muscle cells in chronic asthma.支气管平滑肌细胞表型调节在慢性哮喘中的潜在作用。
Can J Physiol Pharmacol. 1994 Nov;72(11):1448-57. doi: 10.1139/y94-209.
8
[Inflammation, hyperresponsiveness and reversible bronchial obstruction in asthma: are they related?].[哮喘中的炎症、高反应性及可逆性支气管阻塞:它们之间有关联吗?]
Recenti Prog Med. 2004 Mar;95(3):157-60.
9
Chronic obstructive pulmonary disease - diagnosis and management of stable disease; a personalized approach to care, using the treatable traits concept based on clinical phenotypes. Position paper of the Czech Pneumological and Phthisiological Society.慢性阻塞性肺疾病 - 稳定期疾病的诊断和管理;基于临床表型的可治疗特征概念,采用个体化护理方法。捷克肺病和结核学会立场文件。
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2020 Dec;164(4):325-356. doi: 10.5507/bp.2020.056.
10
IL-5 and IL-5 receptor in asthma.哮喘中的白细胞介素-5和白细胞介素-5受体
Mem Inst Oswaldo Cruz. 1997;92 Suppl 2:75-91. doi: 10.1590/s0074-02761997000800012.

引用本文的文献

1
Real-World Use of MART in Moderate-Severe Asthma: Results from the Italian WAMP Survey among Healthcare Professionals and Patients.MART在中重度哮喘中的实际应用:意大利医疗保健专业人员和患者WAMP调查结果
Pulm Ther. 2025 Sep;11(3):475-489. doi: 10.1007/s41030-025-00310-5. Epub 2025 Aug 4.
2
Serum microRNA expression quantitative trait loci in children with asthma colocalize with asthma-related GWAS results.哮喘患儿血清微小RNA表达数量性状位点与哮喘相关全基因组关联研究结果共定位。
NPJ Genom Med. 2025 Jul 17;10(1):55. doi: 10.1038/s41525-025-00510-7.
3
DNA-methylation markers associated with lung function at birth and childhood reveal early life programming of inflammatory pathways.

本文引用的文献

1
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial.贝那鲁肽治疗高剂量吸入性皮质激素和长效β-agonists 控制不佳的严重哮喘患者的疗效和安全性(SIROCCO):一项随机、多中心、安慰剂对照的 3 期临床试验。
Lancet. 2016 Oct 29;388(10056):2115-2127. doi: 10.1016/S0140-6736(16)31324-1. Epub 2016 Sep 5.
2
Serious Asthma Events with Budesonide plus Formoterol vs. Budesonide Alone.布地奈德联用福莫特罗与单用布地奈德治疗严重哮喘事件的比较。
N Engl J Med. 2016 Sep 1;375(9):850-60. doi: 10.1056/NEJMoa1511190.
3
与出生时及儿童期肺功能相关的DNA甲基化标记揭示了炎症通路的早期生命编程。
bioRxiv. 2025 May 14:2025.05.12.653131. doi: 10.1101/2025.05.12.653131.
4
Asthma treatment response modified by fine particulate matter, nitrogen dioxide, and ozone among Black children: A reanalysis of the AsthmaNet Best African American Response to Asthma Drugs trial.黑人儿童中细颗粒物、二氧化氮和臭氧对哮喘治疗反应的影响:哮喘网最佳非裔美国人哮喘药物反应试验的重新分析
J Allergy Clin Immunol. 2025 Apr 15. doi: 10.1016/j.jaci.2025.04.009.
5
Integration of functional genomics and statistical fine-mapping systematically characterizes adult-onset and childhood-onset asthma genetic associations.功能基因组学与统计精细定位的整合系统地表征了成人发病型和儿童发病型哮喘的遗传关联。
Genome Med. 2025 Apr 10;17(1):35. doi: 10.1186/s13073-025-01459-z.
6
Integration of functional genomics and statistical fine-mapping systematically characterizes adult-onset and childhood-onset asthma genetic associations.功能基因组学与统计精细定位的整合系统地表征了成人发病型和儿童发病型哮喘的遗传关联。
medRxiv. 2025 Feb 17:2025.02.11.25322088. doi: 10.1101/2025.02.11.25322088.
7
Modification of asthma treatment efficacy by healthcare access: A reanalysis of AsthmaNet Step-Up Yellow Zone Inhaled Corticosteroids to Prevent Exacerbations (STICS) clinical trial.医疗保健获取对哮喘治疗效果的影响:对哮喘网络升级黄区吸入皮质激素预防加重(STICS)临床试验的重新分析。
Respir Med. 2024 Nov-Dec;234:107853. doi: 10.1016/j.rmed.2024.107853. Epub 2024 Nov 5.
8
Anti-aminoacyl-tRNA synthetase-interacting multifunctional protein-1 antibody improves airway inflammation in mice with house dust mite induced asthma.抗氨酰-tRNA合成酶相互作用多功能蛋白1抗体可改善屋尘螨诱导的哮喘小鼠的气道炎症。
World Allergy Organ J. 2024 Aug 22;17(9):100956. doi: 10.1016/j.waojou.2024.100956. eCollection 2024 Sep.
9
Human milk oligosaccharides are associated with maternal genetics and respiratory health of human milk-fed children.人乳寡糖与人乳喂养儿童的母体遗传学和呼吸健康有关。
Nat Commun. 2024 Sep 4;15(1):7735. doi: 10.1038/s41467-024-51743-6.
10
Assessing the Impact of Spatial and Temporal Variability in Fine Particulate Matter Pollution on Respiratory Health Outcomes in Asthma and COPD Patients.评估细颗粒物污染的时空变异性对哮喘和慢性阻塞性肺疾病患者呼吸健康结局的影响。
J Pers Med. 2024 Aug 6;14(8):833. doi: 10.3390/jpm14080833.
Safety of Adding Salmeterol to Fluticasone Propionate in Children with Asthma.
沙美特罗替卡松丙酸酯加用安全性在哮喘儿童中。
N Engl J Med. 2016 Sep 1;375(9):840-9. doi: 10.1056/NEJMoa1606356.
4
Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial.CXCR2 拮抗剂 AZD5069 治疗未控制的持续性哮喘患者的疗效和安全性:一项随机、双盲、安慰剂对照试验。
Lancet Respir Med. 2016 Oct;4(10):797-806. doi: 10.1016/S2213-2600(16)30227-2. Epub 2016 Aug 27.
5
Inflammatory and Comorbid Features of Patients with Severe Asthma and Frequent Exacerbations.重度哮喘和频繁发作患者的炎症及共病特征
Am J Respir Crit Care Med. 2017 Feb 1;195(3):302-313. doi: 10.1164/rccm.201602-0419OC.
6
Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.度普利尤单抗在吸入中至高剂量皮质类固醇激素联合长效β2 激动剂治疗控制不佳的持续性哮喘成人患者中的疗效和安全性:一项随机、双盲、安慰剂对照的 2b 期关键剂量范围研究。
Lancet. 2016 Jul 2;388(10039):31-44. doi: 10.1016/S0140-6736(16)30307-5. Epub 2016 Apr 27.
7
Childhood asthma exacerbations and the Arg16 β2-receptor polymorphism: A meta-analysis stratified by treatment.儿童哮喘急性发作与精氨酸16β2-肾上腺素能受体基因多态性:一项按治疗分层的荟萃分析
J Allergy Clin Immunol. 2016 Jul;138(1):107-113.e5. doi: 10.1016/j.jaci.2015.10.045. Epub 2016 Jan 7.
8
Clinical Implications of Having Reduced Mid Forced Expiratory Flow Rates (FEF25-75), Independently of FEV1, in Adult Patients with Asthma.成年哮喘患者中,独立于第一秒用力呼气容积(FEV1)之外的用力呼气中期流速(FEF25-75)降低的临床意义
PLoS One. 2015 Dec 30;10(12):e0145476. doi: 10.1371/journal.pone.0145476. eCollection 2015.
9
The effectiveness of school-based family asthma educational programs on the quality of life and number of asthma exacerbations of children aged five to 18 years diagnosed with asthma: a systematic review protocol.以学校为基础的家庭哮喘教育项目对5至18岁确诊哮喘儿童生活质量和哮喘发作次数的有效性:一项系统评价方案
JBI Database System Rev Implement Rep. 2015 Oct;13(10):69-81. doi: 10.11124/jbisrir-2015-2335.
10
Albuterol Overuse: A Marker of Psychological Distress?沙丁胺醇过度使用:心理困扰的一个指标?
J Allergy Clin Immunol Pract. 2015 Nov-Dec;3(6):957-62. doi: 10.1016/j.jaip.2015.06.021. Epub 2015 Sep 1.